A. Wieczorek

465 total citations
22 papers, 395 citations indexed

About

A. Wieczorek is a scholar working on Molecular Biology, Surgery and Genetics. According to data from OpenAlex, A. Wieczorek has authored 22 papers receiving a total of 395 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Molecular Biology, 3 papers in Surgery and 3 papers in Genetics. Recurrent topics in A. Wieczorek's work include Cancer, Lipids, and Metabolism (3 papers), Lipoproteins and Cardiovascular Health (3 papers) and Protein Kinase Regulation and GTPase Signaling (3 papers). A. Wieczorek is often cited by papers focused on Cancer, Lipids, and Metabolism (3 papers), Lipoproteins and Cardiovascular Health (3 papers) and Protein Kinase Regulation and GTPase Signaling (3 papers). A. Wieczorek collaborates with scholars based in Germany, Switzerland and Poland. A. Wieczorek's co-authors include L H Block, Claudio Rhyner, Agapios Sachinidis, H. Vetter, Yon Ko, Y. Ko, N. Zöllner, F. A. Spengel, G Wolfram and André P. Perruchoud and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Biochemical and Biophysical Research Communications and Atherosclerosis.

In The Last Decade

A. Wieczorek

21 papers receiving 368 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
A. Wieczorek Germany 12 199 97 93 83 73 22 395
James S. Bean United States 11 161 0.8× 51 0.5× 94 1.0× 74 0.9× 111 1.5× 16 414
Maria Bürgin Switzerland 12 206 1.0× 50 0.5× 66 0.7× 38 0.5× 55 0.8× 18 470
Mitsuru Notoya Japan 13 245 1.2× 47 0.5× 55 0.6× 110 1.3× 62 0.8× 31 528
Zhang Ji China 5 191 1.0× 99 1.0× 82 0.9× 159 1.9× 154 2.1× 12 459
Jutta Meyer-Kirchrath Germany 15 211 1.1× 63 0.6× 146 1.6× 52 0.6× 29 0.4× 24 652
Nermin Ali Japan 13 278 1.4× 82 0.8× 45 0.5× 76 0.9× 38 0.5× 18 506
Anna Helgadóttir Iceland 10 241 1.2× 64 0.7× 193 2.1× 123 1.5× 60 0.8× 16 582
Victoria R. Cook United States 12 221 1.1× 81 0.8× 125 1.3× 199 2.4× 196 2.7× 14 518
Maryvonne Moisant France 8 208 1.0× 38 0.4× 66 0.7× 156 1.9× 25 0.3× 11 372
Heidi E. Lilja Finland 8 239 1.2× 57 0.6× 181 1.9× 237 2.9× 160 2.2× 9 624

Countries citing papers authored by A. Wieczorek

Since Specialization
Citations

This map shows the geographic impact of A. Wieczorek's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. Wieczorek with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. Wieczorek more than expected).

Fields of papers citing papers by A. Wieczorek

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A. Wieczorek. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. Wieczorek. The network helps show where A. Wieczorek may publish in the future.

Co-authorship network of co-authors of A. Wieczorek

This figure shows the co-authorship network connecting the top 25 collaborators of A. Wieczorek. A scholar is included among the top collaborators of A. Wieczorek based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A. Wieczorek. A. Wieczorek is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Skuza, G, Zofia Rogóż, & A. Wieczorek. (1997). Neuropsychopharmacological profile of remoxipride in comparison with clozapine.. PubMed. 49(1). 5–15. 9 indexed citations
2.
Fritsch, Holger, et al.. (1997). [Postmenopausal hormone substitution and its effects on the climacteric syndrome, body weight and blood pressure].. PubMed. 119(3). 128–32. 3 indexed citations
3.
Sachinidis, Agapios, Y. Ko, A. Wieczorek, et al.. (1993). Lipoproteins Induce Expression of the Early Growth Response Gene-1 in Vascular Smooth Muscle Cells from Rat. Biochemical and Biophysical Research Communications. 192(2). 794–799. 27 indexed citations
4.
5.
Wieczorek, A., et al.. (1993). High-density lipoprotein reduces epidermal growth factor-induced DNA synthesis in vascular smooth muscle cells. Atherosclerosis. 99(2). 253–259. 21 indexed citations
6.
Sachinidis, Agapios, Yon Ko, Peter Weißer, et al.. (1993). EXP3174, a metabolite of losartan (MK954, DuP753) is more potent than losartan in blocking the angiotensin ll-induced responses in vascular smooth muscle cells. Journal of Hypertension. 11(2). 155–162. 47 indexed citations
7.
8.
Sachinidis, Agapios, et al.. (1992). The effect of angiotensin II on DNA synthesis varies considerably in vascular smooth muscle cells from different Wistar???Kyoto rats. Journal of Hypertension. 10(10). 1159–1164. 21 indexed citations
9.
Ko, Y., et al.. (1992). Inhibition of angiotensin II and platelet-derived growth factor-induced vascular smooth muscle cell proliferation by calcium entry blockers. Journal of Molecular Medicine. 70(2). 113–7. 23 indexed citations
10.
Sachinidis, Agapios, et al.. (1992). Action of Metoprolol, Enalapril, Diltiazem, Verapamil, and Nifedipine on Cell Growth of Vascular Smooth Muscle Cells. Journal of Cardiovascular Pharmacology. 19(Supplement 2). S60–S62. 8 indexed citations
11.
Wieczorek, A., et al.. (1992). Losartan inhibits the angiotensin II-induced stimulation of the phosphoinositide signalling system in vascular smooth muscle cells. European Journal of Pharmacology Molecular Pharmacology. 227(2). 215–219. 11 indexed citations
12.
Rhyner, K, et al.. (1989). Serumerythropoietinwerte bei verschiedenen Krankheitszuständen. ˜The œNephron journals/Nephron journals. 51(1). 39–46. 6 indexed citations
13.
Egli, F, et al.. (1988). [Polycythemia vera: clinical aspects and course in 86 patients].. PubMed. 118(52). 1969–75. 6 indexed citations
14.
Wieczorek, A., et al.. (1987). Diagnostic and prognostic value of RNA-proteolipid in sera of patients with malignant disorders following therapy: first clinical evaluation of a novel tumor marker.. PubMed. 47(23). 6407–12. 38 indexed citations
15.
Wieczorek, A., Claudio Rhyner, & L H Block. (1985). Isolation and characterization of an RNA-proteolipid complex associated with the malignant state in humans.. Proceedings of the National Academy of Sciences. 82(10). 3455–3459. 82 indexed citations
16.
Wieczorek, A. & N. Zöllner. (1985). Increase in glycosaminoglycan synthesis in familial hypercholesterolemic fibroblasts.. Arteriosclerosis An Official Journal of the American Heart Association Inc. 5(5). 434–439. 1 indexed citations
17.
Keller, C., et al.. (1981). Serum cholesterol levels in patients with familial hypercholesterolemia confirmed by tissue culture. Atherosclerosis. 39(1). 51–59. 17 indexed citations
18.
Wieczorek, A. & N. Zöllner. (1978). [Differentiation characteristics for the identification of patients with familial hypercholesteremia - studies on skin fibroblasts].. PubMed. 83. 381–2. 1 indexed citations
19.
Dörfler, H.‐D., A. Wieczorek, C. A. Barth, G. Wolfram, & N. Zöllner. (1978). [Relationship between insulin binding and insulin effect in a special form of insulin resistance].. PubMed. 1204–6. 1 indexed citations
20.
Dörfler, H.‐D., A. Wieczorek, G Wolfram, & N. Zöllner. (1977). Binding of insulin to fibroblasts in lipoatrophic diabetes. Research in Experimental Medicine. 170(2). 161–168. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by James S. Bean Breakdown of academic impact, for papers by Maria Bürgin Breakdown of academic impact, for papers by Mitsuru Notoya Breakdown of academic impact, for papers by Zhang Ji Breakdown of academic impact, for papers by Jutta Meyer-Kirchrath Breakdown of academic impact, for papers by Nermin Ali Breakdown of academic impact, for papers by Anna Helgadóttir Breakdown of academic impact, for papers by Victoria R. Cook Breakdown of academic impact, for papers by Maryvonne Moisant Breakdown of academic impact, for papers by Heidi E. Lilja
Rankless by CCL
2026